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Abstract
This paper presents an NMR crystallography study of three polymorphs of
furosemide. Experimental magic-angle spinning (MAS) solid-state NMR spec-
tra are reported for form I of furosemide, and these are assigned using
density-functional theory (DFT)-based gauge-including projector augmented
wave (GIPAW) calculations. Focusing on the three known polymorphs, we
examine the changes to the NMR parameters due to crystal packing effects. We
use a recently developed formalism to visualise which regions are responsible
for the chemical shielding of particular sites and hence understand the variation
in NMR parameters between the three polymorphs.
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1 INTRODUCTION
A definition for polymorphism was given by McCrone in
1965: a polymorph is a solid crystalline phase of a given
compound resulting from the possibility of at least two dif-
ferent arrangements of the molecules of that compound in
the solid state.[1] Polymorphism is a common phenomena,
with one in three compounds in the Cambridge Struc-
tural Database (CSD) exhibiting polymorphism.[2] When
several polymorphs exist, they will often exhibit different
macroscopic properties despite having the samemolecular
composition. Variations can be observed in, for example,
stability, strength, and elasticity.[3] For the pharmaceutical
industry, the bioavailability of a compound is of partic-
ular importance since it can determine if a drug can be
administrated as a tablet or not. An active pharmaceutical
ingredientcanhavealowsolubility inwater inoneformand
a more desirable solubility in another form or a cocrystal.
The key to a crystal's macroscopic characteristics is
found in its microscopic packing arrangement. Although
composed of the same molecular units, the molecules
can interact with each other differently resulting in dif-
ferent properties. The polymorphs can vary in unit-cell
dimensions, symmetries, intermolecular bonds, stacking
arrangements, and conformational changes in the molec-
ular unit itself.
Solid-state nuclear magnetic resonance (NMR) is a
highly sensitive probe of the local atomic environment,
making it an effective tool for distinguishing between
similar polymorphs.[10–12] Under the umbrella of NMR
crystallography,[13–15] solid-state NMR experiments can be
used in conjunction with first-principles calculations, for
example using the gauge-including projector augmented
wave (GIPAW) approach,[16,17] to validate structures solved
by powder X-Ray diffraction (pXRD). Solid-state NMR,
being a sensitive local probe,[10,18–21] has a complemen-
tary nature to pXRD that relies on long-range order. With
first-principles GIPAW calculations tying these two tech-
niques together, NMR crystallography has a proven track
record in analysing and validating solid structures.[22–28]
The influence of intermolecular effects on NMR chem-
ical shifts can be studied by comparing the calculated
chemical shifts from an isolated molecule extracted from
the crystal structure to the calculated chemical shifts for
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Scheme 1
the full crystal structure.[18,20,29,30] This difference reflects
two contributions: long-range effects of current elements,
for example, ring currents, and local changes in electronic
structure that result from crystal packing, for example,
hydrogen bonding. The nuclear independent chemical
shift (NICS)[31,32] can be used to identify aromatic ring cur-
rents that can have a strong effect on the 1H solid-state
NMR chemical shift.[30,33]
Furosemide (Scheme 1) is an active pharmaceuti-
cal ingredient marketed under the brand name Lasix.
Furosemide is used to relieve congested fluids in partly or
fully failing organs such as the heart, liver, and kidney[34]
and is also used to treat hypertension.[35] Furosemide has
three known forms, with 10 entries in the CSD. See Table 1
for a summary of all entries and Figure 1 for represen-
tations of the crystal structures of the three forms. The
correct form[36] of form I is known to have Z′ = 2 and
Z = 4, and a recent study using GIPAW calculations
that considered FURSEM01, FURSEM17, and a new form
and solid-state NMR experiments has determined that
FURSEM17 is likely an inaccurate solution of form I.[9]
Unfortunately, furosemide has poor bioavailability[37–39]
and furosemide cocrystals[40–42] have been synthesised in
an attempt to improve the solubility in water. Furosemide
and its cocrystals have been previously studied using
solid-state NMR.[42–47] Dissolution kinetics of furosemide
form I have also recently been studied using in situ 3D
microscopy.[48]
In this study, we analyse three solutions for form I:
FURSEM01 (F01),[5] FURSEM03 (F03),[6] and FURSEM13
(F13)[7] and one solution for each of forms II and III,
FURSEM14 (F14)[7] and FURSEM16 (F16),[7] respectively.
For form I of furosemide, the calculated values are com-
pared with solid-state NMR experimental spectra obtained
using 13C CP magic-angle spinning (MAS), 1H–13C refo-
cused INEPT, and 1H double quantum (DQ) MAS exper-
iments. The GIPAW-calculated NMR chemical shifts are
TABLE 1 CSD entries for furosemide
Form I P1̄ Z′ = 2 FURSEM[4] FURSEM01[5]
FURSEM02[5] FURSEM03[6]
FURSEM13[7] FURSEM17[8]
FURSEM18[9]
Form II P21∕n Z′ = 1 FURSEM14[7] FURSEM15[7]
Form III P1̄ Z′ = 1 FURSEM16[7]
Note. FURSEM02 has Z′ = 1. CSD: Cambridge Structural Database.
Figure 1 Crystal structures for furosemide polymorphs. Same
coloured molecules are related by symmetry. (a) Form I
(FURSEM01), (b) Form II (FURSEM14), and (c) Form III
(FURSEM16)
analysed focusing on intermolecular hydrogen bonding
and aromatic ring current effects. The analysis notes sub-
tleties between solved structures of the same form, and
different geometry optimization approaches.
2 EXPERIMENTAL AND
COMPUTATIONAL DETAILS
2.1 Experimental details
Furosemide was purchased from Sigma-Aldrich (Gilling-
ham, UK). Solid-state NMR experiments were performed
using Bruker Avance III NMR spectrometers operating
at a 1H Larmor frequency of 500.1MHz (13C Larmor
frequency of 125.8MHz). A Bruker 4-mm triple reso-
nance MAS probe (in double-resonance mode) was used
in 1H–13C CP MAS and refocused INEPT experiments,
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and a Bruker 2.5-mm double resonance MAS probe was
used for the 1H DQ experiment. In 1H–13C CP MAS and
refocused INEPT experiments, SPINAL64 1H heteronu-
clear decoupling[49] with a pulse duration of 2.5𝜇s was
applied for an acquisition time of 40ms. The 1H nutation
frequency for pulses and decoupling was 100 kHz.
A pulse sequence and coherence transfer pathway dia-
gram for the 1H (SQ-DUMBO)–13C SQ refocused INEPT
experiment can be found in Fig. 5 of Elena et al.,[50]
and for 1H DQ MAS,[51] using BABA (back-to-back)
recoupling[52,53] in Fig. 7 of Brown and Spiess.[54] For the
1H DQMAS experiment, a 16-step phase cycle was used to
select Δp = ±2 on the DQ excitation pulses (four steps)
andΔp = ±1 (four steps) on the z-filter 90◦ pulse, where p
is the coherence order. For the 2D 1H–13C refocused INEPT
experiment, eDUMBO-122 homonuclear decoupling,[55,56]
was employed during the 1H evolution period and the
spin-echo durations. The 32-𝜇s eDUMBO-122 cycle was
divided into 320 steps of 100 ns. The STATES-TPPImethod
was used to achieve sign determination in F1 in the refo-
cused INEPT and DQMAS experiments.
2.2 Computational details
Calculations were performed using a developer version
of the CASTEP code[57] together with the CASTEP9
set of ultrasoft pseudopotentials.[58] The cut-off for the
basis set was 800 eV, and the Brillouin Zone was sam-
pled using a Monkhorst Pack[59] grid with a minimum
spacing of 0.05 × 2𝜋 Å−1. All crystal structures were
optimised using the Perdew-Burke-Ernzerhof (PBE)[60]
functional together with dispersion corrections using the
Tkatchenko-Scheffler (TS) scheme.[61] Two separate geom-
etry optimisations were performed for each structure: In
the first case (denoted “fixed cell”), only the internal coor-
dinates were allowed to change, with the unit cell dimen-
sions fixed to the X-ray diffraction derived values. In the
second case (denoted “relaxed cell”), both unit cell param-
eters and internal coordinates were able to relax during
the optimisation. Calculations of NMR magnetic shield-
ings were computed using the GIPAW approach.[16,17] All
crystal structures and full shielding tensors for all atoms
are made available as a downloadable data set. Structure
views for Figure 6were generated usingVESTA3[62]; struc-
ture views for Figure 1 and root-mean-square deviation of
atomic positions were generated using Mercury CSD.[63]
2.3 Molecule to crystal change
in magnetic shielding and NICS
Isotropic chemical shifts, 𝛿iso, are related to the calculated
isotropicmagnetic shieldings, 𝜎iso, by a reference value 𝜎ref
(all in ppm):
𝛿iso = 𝜎re𝑓 − 𝜎iso. (1)
The necessary magnetic shielding calculations to com-
pute the molecule to crystal change in chemical shift and
the NICS are illustrated in Fig. 1 of Zilka et al.[64] The first
calculation (denoted Ifullcell) is of a single crystallographic
unit cell. The second calculation (denoted Inomol) is per-
formed on a unit cell of the crystal with the molecule that
contains the atom of interest removed. Depending on the
crystal structure, it may be necessary to simulate a super-
cell of the unit cell, such that the missing molecule is
surrounded by all of its nearest neighbours. In this work, a
2 × 1 × 1 supercell was used for the NICS calculations of
all three polymorphs.* The NICS, 𝜎NICS, is obtained from
calculating the value of the magnetic shielding at the site
of the atom in the missing molecule. The final calcula-
tion (denoted IIIonemol) is a vacuum supercell with only one
molecule containing the atom of interest. The molecule
to crystal change in chemical shifts Δ𝛿 is the change in
shifts between calculations IIIonemol and Ifullcell. Within this
setup, we can analyse all intermolecular effects. The values
denoted as “H bond strength” correspond to the sum of the
molecule to crystal change in chemical shift and the NICS;
as such, this accounts for changes in the NMR chemical
shift due to interactions between a specific molecule and
its neighbours.
3 RESULTS
3.1 Form I of furosemide
A 13C CP MAS spectrum of furosemide form I, recorded
at room temperature, is presented in Figure 2. Furosemide
form I contains two molecules in the asymmetric unit
(Z′ = 2), each with 12 carbon atoms, corresponding to,
at most, 24 peaks in the 13C spectrum. The 13C CP MAS
spectrum is consistent with previously reported data.[45]
The spectrum was assigned using the GIPAW calculated
chemical shifts from the geometry optimised (relaxed)
FURSEM01 unit cell. The fit between the experimental
spectrum and the calculated peaks is very good with the
exception of the carbon atoms closest to the sulfur atom
(V′). Moreover, the splitting in the values of the chemical
shift between the two inequivalent molecules is also well
reproduced. In Figure 3, the experimental 13C chemical
shifts are plotted against the GIPAW-calculated absolute
isotropic 13C chemical shielding of furosemide form I. The
(negative) gradient (see Equation 1) was allowed to devi-
ate from unity. It is common practice to also fit the data
while constraining the gradient to unity[28]; however, with
the unconstrained slope being 1.01, no additional fit was
done. The intercept with the y-axis usually determines
*FURSEM01 does not employ the convention 𝛼 < 𝛽 < 𝛾 , and 𝛼 and 𝛾
are swapped. To account for this, a 1 × 1 × 2 supercell was used.
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FIGURE 2 A 1H (500 MHz)-13C CP (2 ms contact time, 800
transients were co-added for a recycle delay of 105 s) MAS (10 kHz)
NMR spectrum of furosemide (form I) (black) with the GIPAW
calculated 13C chemical shifts for FURSEM01 overlaid in red
FIGURE 3 Plot of the experimental 13C chemical shifts of
furosemide (form I) against the GIPAW calculated absolute isotropic
13C shielding for the 12 carbon atoms in the two distinct furosemide
molecules in the asymmetric unit cell (FURSEM01). The line of
best fit had not been constrained to a gradient equal to −1
the reference shielding, 𝜎ref, used to relate calculated and
experimental chemical shifts.
A 2D 1H–13C refocused INEPT[50] spectrum is shown
in Figure 4. The spectrum was recorded using moder-
ate 12.5-kHz MAS, with eDUMBO-122 1H homonuclear
decoupling, with short spin-echo durations selective for
the observation of direct one bond CH connectivities. The
experimental spectrum is overlaid with the GIPAW cal-
culated 1H and 13C chemical shifts. Because only a small
region of the full 13C chemical shift range is presented in
Figure 4, a small variation from the derived value for all 13C
chemical shifts in Figure 3 of 𝜎ref = 173 ppm was allowed
for a better fit to experiment.[19] The assignment wasmade
against chemical shifts calculated from the geometry opti-
mised (relaxed) FURSEM01 structure, and the fit is good
and is compatible with a published 1H–13C CP-HETCOR
MAS NMR spectrum and GIPAW calculation by Widdi-
field et al.[9] Note that in this J-coupling-based 1H–13C refo-
cused INEPT experiment, we do not observe the H6 and
H6' peaks found at 8.4 ppm for the dipolar-coupling-based
1H–13C CP-HETCOR experiment in Widdifield et al.[9]
(Note that the purple contours observed in the 1H dimen-
sion at 6 and 10 ppm between 134 and 136 ppm in the 13C
dimension are at the level of experimental noise.)
Figure 5 presents a 1H DQMAS spectrum of furosemide
form I recorded using fast MAS (30 kHz). The peaks cor-
respond to pairs of protons with a significant (typically
<3.5Å)[51] dipolar interaction, that is, they are close to
each other in space. Experimentally, it is not possible
to differentiate between intramolecular and intermolecu-
lar interactions. Using the MagresView software,[65] the
GIPAW calculated chemical shifts are represented as over-
laid crosses, with a dipolar coupling weighting. The peaks
are assigned to specific H–H pairs, and contributions both
from intramolecular and intermolecular contributions are
present.
3.2 Furosemide CSD deposited structures
and polymorphs
Having considered a comparison of experimental NMR
spectra and GIPAW calculations of form I of furosemide,
we now use first-principles calculations to assess the accu-
racy of the alternative XRD structures deposited for form
I. We also examine the structures of the other two known
forms of furosemide. Table 2 and 3 present the unit cell
parameters and the dispersion-corrected free energies of
the geometry optimised structures, respectively. The three
form I structures are close in energy—after a fixed cell opti-
misation, the three structures lie within 0.8 kJmol−1; how-
ever, after a full relaxation, this is reduced to 0.1 kJmol−1.
Form I is known to be the experimentally most stable poly-
morph, and indeed, it has the lowest total energy, with
forms II and III, 1.3 and 2.6 kJmol−1 higher, respectively.
Note that Nyman and Day showed that, for an analysis
of over 500 organic molecular polymorphs, 95% of poly-
morphs are within 7.2 kJmol−1.[66]
NMR chemical shieldings have been calculated using
the GIPAW method for all the geometry optimised
furosemide structures. The full GIPAWcalculated absolute
chemical shielding for each distinct site in the asymmetric
unit cells is presented in the Supporting Information.
The energetic similarity of the three form I structures is
reflected in the root-mean-square deviation of atomic posi-
tion. This is shown in Table 4. As expected, the differences
between the fixed unit cell structures are greater than
that between the relaxed unit cell structures. Table 5 sum-
marises the differences in 1H magnetic shielding between
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FIGURE 4 A 1H (500MHz)-13C refocused INEPT (eDUMBO-122 1H homonuclear decoupling) MAS (12.5 kHz) NMR spectrum, together
with skyline projections, of furosemide form I, recorded using a spin-echo (𝜏 – 𝜋 – 𝜏) duration, 𝜏 = 𝜏 ′ = 0.96ms. Two hundred and fifty-six
transients were coadded for each of 26 t1 FIDs for a recycle delay of 60 s, corresponding to a total experimental time of 4 days and 15 hr. The
base contour level is at 15%. Crosses (in red) correspond to the GIPAW calculated 13C and 1H chemical shifts for directly bonded CHmoieties,
using 𝜎ref = 29.6 ppm for 1H and 𝜎ref = 168.4 ppm for 13C for the geometry optimised (CASTEP) crystal structure of furosemide form I
based on CSD structure FURSEM01
FIGURE 5 A 1H (500MHz) DQMAS (30 kHz) NMR spectrum, together with skyline projections, of furosemide from I, recorded using one
rotor period of BABA recoupling. Sixty-four transients were coadded for each of 256 t1 FIDs for a recycle delay of 3 s, corresponding to a total
experimental time of 13.8 hr. The base contour level is at 7% of the maximum peak height. The F1 = 2F2 diagonal is shown as a dashed line.
Horizontal lines (in light blue) indicate pairs of DQ peaks corresponding to close (<3.5 Å) H–H proximities. Crosses represent the GIPAW
calculated shift with a dipolar coupling weighting. A partial assignment of the peaks is presented on the spectrum. The number refers to the
label of the hydrogen (see Scheme 1) and the superscript to the molecular unit (a or b, corresponding to the two molecules in the asymmetric
unit)
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TABLE 2 Unit cell parameters and volume for fixed cell and relaxed cell
geometry optimisations of furosemide CSD entries (see Table 1)
Unit cell parameters Volume per
a b c 𝜶 𝜷 𝜸 molecule
(Å) (Å) (Å) (◦) (◦) (◦) (Å3)
F01 fixed 9.58 10.47 15.80 93.47 107.27 115.04 333.21
F01 relaxed 9.65 10.45 15.69 92.63 107.38 116.48 328.20
F03 fixed 9.59 10.50 15.71 93.06 107.22 116.21 331.21
F03 relaxed 9.65 10.45 15.61 92.65 107.33 116.57 328.80
F13 fixed 9.52 10.45 15.58 92.84 107.09 116.75 322.98
F13 relaxed 9.66 10.44 15.63 92.62 107.38 116.53 329.18
F14 fixed 5.01 10.11 26.62 90.00 95.40 90.00 335.52
F14 relaxed 5.05 10.03 26.55 90.00 94.38 90.00 335.04
F16 fixed 4.88 10.50 13.64 78.07 86.72 82.59 338.64
F16 relaxed 4.93 10.47 13.62 78.91 86.08 82.03 341.60
TABLE 3 Dispersion-corrected final free energy differences (in
kJmol−1) between geometry optimised structures of furosemide
(See Table 1)
I II III
F01a F03 F13 F14 F16
Fixed 1.159 0.591 0.379 1.915 2.976
Relaxed 0.000 0.047 0.095 1.321 2.625
a F01 relaxed is the reference structure.
TABLE 4 Root-mean-square deviation of atomic position (in Å)
between geometry optimised structures of furosemide (See Table 1;
from an overlay of 15 molecules, protons are included)
F01 F03 F13 F01 F03 F13
fixed fixed fixed relaxed relaxed relaxed
F01 fixed
F03 fixed 0.073
F13 fixed 0.140 0.088
F01 relaxed 0.106 0.076 0.103
F03 relaxed 0.106 0.064 0.097 0.024
F13 relaxed 0.104 0.061 0.102 0.040 0.021
TABLE 5 Maximal difference in chemical GIPAW calculated
shielding values and NICS and “H bond strength” (in ppm) for 1H
nuclei (see Table 6; between geometry optimised form I structures:
FURSEM01, FURSEM03, and FURSEM13
Isolated Full Difference NICS H bond
molecule crystal (Mol–Crys) strength
Relaxed mol a 0.06 0.08 0.07 0.07 0.06
mol b 0.06 0.07 0.07 0.09 0.10
Fixed mol a 0.09 0.20 0.19 0.13 0.19
mol b 0.13 0.18 0.19 0.10 0.14
the form I structures. The full GIPAW calculated magnetic
shieldings for each distinct site in the asymmetric unit cells
are presented in the Supporting Information. The maxi-
mal difference between the values is 0.2 ppm for structures
after a fixed unit cell geometry optimisation. However, if
we compare the structures that were geometry optimised
under relaxed unit cell conditions, we see that the differ-
ence in shielding values minimise to a maximal difference
of 0.08 ppm. This difference is comparable to the precision
available in the solid-state NMR experiments and much
less than the typical discrepancy between GIPAW calcu-
lated and experimental chemical shifts. This shows us that,
as far as NMR crystallography is concerned, each of the
three form I structures (F01, F03, and F13) are an equally
valid starting point, and the resulting relaxed unit cell
structures are essentially indistinguishable.
Wenow examine the changes in chemical shifts between
the three polymorphs. A full listing of the GIPAW calcu-
lated chemical shifts values of the furosemide polymorphs,
form I, II, and III, can be found in Table 6. When compar-
ing different forms, the first component to examine is the
calculated chemical shifts in an isolated molecule calcu-
lation. This is free from any effect due to intermolecular
interactions. If the molecular conformations in the three
forms are very similar, then the isolatedmolecule chemical
shifts will be very similar. The only difference of >1 ppm
exists for H8 between form III (F16) and the other configu-
rations (1.68, 1.33, and 1.55 ppm difference with molecule
a F01, molecule a F01, and F14, respectively). Between
the three forms, the individual molecules display a vari-
ety of torsion angles about the N–C bond. However, the
critical factor affecting the H8 1H chemical shift appears
to be the angle between the N–C bond and the furan
ring. This is 93◦ in form III as compared with 111◦ and
114◦ for the other cases. Themolecule to crystal changes in
chemical shift encompass the effect due to intermolecular
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TABLE 6 GIPAW calculated chemical shiftsa and NICS (in ppm)
for the hydrogen atoms in three furosemide polymorphs
I
F01 II III
mol a mol b F14 F16
Isolated OH 1 5.96 6.18 5.65 5.69
molecule NH 2 7.64 8.09 7.95 8.44
CH 3 5.76 5.32 5.26 5.91
NH2 4 3.41 4.11 3.18 3.19
NH2 5 4.09 3.50 3.92 4.49
CH 6 7.38 7.52 7.52 7.60
CH2 7 3.43 3.33 2.73 3.29
CH2 8 2.86 3.21 2.99 4.54
CH 9 5.29 5.46 5.29 5.54
CH 10 5.42 5.44 5.52 5.49
CH 11 6.64 6.69 6.72 6.63
Full OH 1 13.46 13.63 12.76 12.92
crystal NH 2 7.47 8.04 7.61 7.92
CH 3 7.02 4.40 4.01 5.25
NH2 4 5.24 6.92 6.47 6.08
NH2 5 6.90 6.42 6.00 5.13
CH 6 7.60 7.49 6.76 7.56
CH2 7 4.25 3.97 2.95 1.83
CH2 8 3.19 3.12 3.92 3.93
CH 9 4.59 5.42 5.32 5.75
CH 10 6.09 5.47 6.25 5.91
CH 11 5.90 7.37 7.37 6.88
Difference OH 1 7.50 7.45 7.12 7.22
(Crys–Mol) NH 2 −0.17 −0.05 −0.34 −0.52
CH 3 1.27 −0.92 −1.25 −0.66
NH2 4 1.83 2.82 3.29 2.89
NH2 5 2.81 2.92 2.08 0.63
CH 6 0.23 −0.03 0.93 −0.04
CH2 7 0.81 0.63 −0.76 −1.45
CH2 8 0.33 −0.09 0.23 −0.61
CH 9 −0.70 −0.04 0.65 0.20
CH 10 0.67 0.03 0.73 0.42
CH 11 −0.74 0.68 0.03 0.26
NICS OH 1 1.32 1.91 1.95 1.58
NH 2 0.14 −0.12 −0.04 0.17
CH 3 −0.43 1.14 1.33 0.61
NH2 4 −0.30 −0.21 −0.71 −0.23
NH2 5 0.04 −0.47 −0.66 0.07
CH 6 −0.13 −0.03 0.67 0.05
CH2 7 −0.43 −0.06 0.23 1.53
CH2 8 0.28 0.77 −0.32 0.41
CH 9 1.52 0.92 0.03 −0.18
CH 10 0.07 0.25 −0.56 −0.01
CH 11 0.90 −0.18 0.23 −0.16
“H bond OH 1 6.18 5.54 5.17 5.64
strength” NH 2 −0.31 0.07 −0.30 −0.69
CH 3 1.70 −2.06 −2.58 −1.27
NH2 4 2.13 3.03 4.00 3.12
NH2 5 2.77 3.39 2.75 0.56
CH 6 0.35 0.00 −1.42 −0.09
CH2 7 1.24 0.70 0.00 −2.98
CH2 8 0.05 −0.86 1.25 −1.02
CH 9 −2.22 −0.95 0.00 0.38
CH 10 0.59 −0.22 1.29 0.43
CH 11 −1.65 0.86 0.42 0.42
Note. NICS: nuclear independent chemical shift.
a𝜎ref = 29.60 ppm.
FIGURE 6 Decomposition maps[64] visualizing the effect of
aromatic ring currents on the NMR chemical shifts of (a) hydrogen
9 in molecule a in FURSEM01, (b) hydrogen 3 in molecule b in
FURSEM01, (c) hydrogen 3 in FURSEM14, and (d) hydrogen 7 in
FURSEM16
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interactions and ring currents combined. This can be fur-
ther decomposed into differences due to hydrogen bonds
and to long-range packing interactions. All forms have
an OH...O hydrogen bond as the strongest intermolecu-
lar bond. In addition, at least one NH...X (where X is
N or O) hydrogen bond exists in all forms, and forms I
and II have two NH...X hydrogen bonds. The differences
in longer range packing interaction are apparent in the
calculated NICS values. In each polymorph, a different
hydrogen interacts with an aromatic ring. The effect of
the ring currents is visualised through Magnetic Shielding
Contribution Field maps[64] shown in Figure 6.
4 CONCLUSIONS
We have presented 13C CP MAS, 1H–13C refocused INEPT
and 1H DQ MAS NMR spectra for form I of furosemide.
The spectra have been assigned by comparisonwith chem-
ical shifts computed using DFT and the GIPAW approach.
We have used DFT calculations to assess the quality of
three of the deposited structures for form I of furosemide.
After a full relaxation of the atomic positions and unit
cell parameters, all three structures are essentially indis-
tinguishable, giving differences in GIPAW calculated 1H
chemical shifts that are well below the precision obtained
in our experiments. Further calculations on forms II and
III of furosemide have employed a recently developed
approach[64] to identify short-range and long-range contri-
butions to the chemical shift and furthermap the chemical
origin of long-range contributions. For the three poly-
morphs of furosemide, this approach highlights how the
differing packing interactions influence the chemical shift,
leading to observable differences in the NMR spectra. This
suggests that such analysis will prove a useful tool in NMR
crystallography.Wenote that thiswork has been used as an
teaching example of NMR crystallography for workshops
(see Supporting Information).
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